Can psychosine and galactocerebrosidase activity predict early-infantile Krabbe's disease presymptomatically?

Randy L. Carter, Lawrence Wrabetz, Kabir Jalal, Joseph J. Orsini, Amy L. Barczykowski, Dietrich Matern, Thomas J. Langan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Krabbe's disease (KD) is a fatal neurodegenerative disorder, with the early-infantile form (EIKD) defined by onset of symptoms before age 6 months. Early and highly accurate identification of EIKD is required to maximize benefits of hematopoietic stem cell transplantation treatment. This study investigates the potential for accurate prediction of EIKD based on a novel newborn screening (NBS) tool developed from two biomarkers, galactocerebrosidase (GALC) enzyme activity and galactosylsphingosine concentration (psychosine [PSY]). Normative information about PSY and GALC, derived from distinct samples of normal newborns, was used to develop the novel diagnostic tool. Bivariate normal limits (BVNL) were constructed, assuming a multivariate normal distribution of natural logarithms of GALC and PSY of normal newborns. The (lnGALC, lnPSY) points for newborns in various “abnormal groups,” including one group of infants who subsequently suffered EIKD, were plotted on a graph of BVNL. The points for all EIKD patients fell outside of BVNL (100% sensitivity). In a simulation study to compare the false-positive rate of existing univariate methods of diagnosis with our new BVNL-based method, we generated 100 million normal newborn data points. All fell within BVNL (i.e., zero false positives), whereas 5,682 false positives were observed when applying a two-tiered univariate method of the type suggested in the literature. These results suggest that (lnGALC, lnPSY) BVNLs will allow highly accurate prediction of EIKD, whereas two-tiered univariate approaches will not. Redevelopment of the BVNL based on GALCs and PSYs measured on a common large sample of normal newborns is required for NBS use.

Original languageEnglish (US)
Pages (from-to)1084-1093
Number of pages10
JournalJournal of Neuroscience Research
Volume94
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Psychosine
Galactosylceramidase
Globoid Cell Leukodystrophy
Newborn Infant
Hematopoietic Stem Cell Transplantation
Normal Distribution
Neurodegenerative Diseases
Biomarkers

Keywords

  • bivariate normal limits
  • early identification
  • early-onset disease
  • followup
  • late-onset disease
  • newborn screening

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Carter, R. L., Wrabetz, L., Jalal, K., Orsini, J. J., Barczykowski, A. L., Matern, D., & Langan, T. J. (2016). Can psychosine and galactocerebrosidase activity predict early-infantile Krabbe's disease presymptomatically? Journal of Neuroscience Research, 94(11), 1084-1093. https://doi.org/10.1002/jnr.23793

Can psychosine and galactocerebrosidase activity predict early-infantile Krabbe's disease presymptomatically? / Carter, Randy L.; Wrabetz, Lawrence; Jalal, Kabir; Orsini, Joseph J.; Barczykowski, Amy L.; Matern, Dietrich; Langan, Thomas J.

In: Journal of Neuroscience Research, Vol. 94, No. 11, 01.11.2016, p. 1084-1093.

Research output: Contribution to journalArticle

Carter, RL, Wrabetz, L, Jalal, K, Orsini, JJ, Barczykowski, AL, Matern, D & Langan, TJ 2016, 'Can psychosine and galactocerebrosidase activity predict early-infantile Krabbe's disease presymptomatically?', Journal of Neuroscience Research, vol. 94, no. 11, pp. 1084-1093. https://doi.org/10.1002/jnr.23793
Carter, Randy L. ; Wrabetz, Lawrence ; Jalal, Kabir ; Orsini, Joseph J. ; Barczykowski, Amy L. ; Matern, Dietrich ; Langan, Thomas J. / Can psychosine and galactocerebrosidase activity predict early-infantile Krabbe's disease presymptomatically?. In: Journal of Neuroscience Research. 2016 ; Vol. 94, No. 11. pp. 1084-1093.
@article{e3a6bbc50ba142139e38bf9d8a3a0355,
title = "Can psychosine and galactocerebrosidase activity predict early-infantile Krabbe's disease presymptomatically?",
abstract = "Krabbe's disease (KD) is a fatal neurodegenerative disorder, with the early-infantile form (EIKD) defined by onset of symptoms before age 6 months. Early and highly accurate identification of EIKD is required to maximize benefits of hematopoietic stem cell transplantation treatment. This study investigates the potential for accurate prediction of EIKD based on a novel newborn screening (NBS) tool developed from two biomarkers, galactocerebrosidase (GALC) enzyme activity and galactosylsphingosine concentration (psychosine [PSY]). Normative information about PSY and GALC, derived from distinct samples of normal newborns, was used to develop the novel diagnostic tool. Bivariate normal limits (BVNL) were constructed, assuming a multivariate normal distribution of natural logarithms of GALC and PSY of normal newborns. The (lnGALC, lnPSY) points for newborns in various “abnormal groups,” including one group of infants who subsequently suffered EIKD, were plotted on a graph of BVNL. The points for all EIKD patients fell outside of BVNL (100{\%} sensitivity). In a simulation study to compare the false-positive rate of existing univariate methods of diagnosis with our new BVNL-based method, we generated 100 million normal newborn data points. All fell within BVNL (i.e., zero false positives), whereas 5,682 false positives were observed when applying a two-tiered univariate method of the type suggested in the literature. These results suggest that (lnGALC, lnPSY) BVNLs will allow highly accurate prediction of EIKD, whereas two-tiered univariate approaches will not. Redevelopment of the BVNL based on GALCs and PSYs measured on a common large sample of normal newborns is required for NBS use.",
keywords = "bivariate normal limits, early identification, early-onset disease, followup, late-onset disease, newborn screening",
author = "Carter, {Randy L.} and Lawrence Wrabetz and Kabir Jalal and Orsini, {Joseph J.} and Barczykowski, {Amy L.} and Dietrich Matern and Langan, {Thomas J.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1002/jnr.23793",
language = "English (US)",
volume = "94",
pages = "1084--1093",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Can psychosine and galactocerebrosidase activity predict early-infantile Krabbe's disease presymptomatically?

AU - Carter, Randy L.

AU - Wrabetz, Lawrence

AU - Jalal, Kabir

AU - Orsini, Joseph J.

AU - Barczykowski, Amy L.

AU - Matern, Dietrich

AU - Langan, Thomas J.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Krabbe's disease (KD) is a fatal neurodegenerative disorder, with the early-infantile form (EIKD) defined by onset of symptoms before age 6 months. Early and highly accurate identification of EIKD is required to maximize benefits of hematopoietic stem cell transplantation treatment. This study investigates the potential for accurate prediction of EIKD based on a novel newborn screening (NBS) tool developed from two biomarkers, galactocerebrosidase (GALC) enzyme activity and galactosylsphingosine concentration (psychosine [PSY]). Normative information about PSY and GALC, derived from distinct samples of normal newborns, was used to develop the novel diagnostic tool. Bivariate normal limits (BVNL) were constructed, assuming a multivariate normal distribution of natural logarithms of GALC and PSY of normal newborns. The (lnGALC, lnPSY) points for newborns in various “abnormal groups,” including one group of infants who subsequently suffered EIKD, were plotted on a graph of BVNL. The points for all EIKD patients fell outside of BVNL (100% sensitivity). In a simulation study to compare the false-positive rate of existing univariate methods of diagnosis with our new BVNL-based method, we generated 100 million normal newborn data points. All fell within BVNL (i.e., zero false positives), whereas 5,682 false positives were observed when applying a two-tiered univariate method of the type suggested in the literature. These results suggest that (lnGALC, lnPSY) BVNLs will allow highly accurate prediction of EIKD, whereas two-tiered univariate approaches will not. Redevelopment of the BVNL based on GALCs and PSYs measured on a common large sample of normal newborns is required for NBS use.

AB - Krabbe's disease (KD) is a fatal neurodegenerative disorder, with the early-infantile form (EIKD) defined by onset of symptoms before age 6 months. Early and highly accurate identification of EIKD is required to maximize benefits of hematopoietic stem cell transplantation treatment. This study investigates the potential for accurate prediction of EIKD based on a novel newborn screening (NBS) tool developed from two biomarkers, galactocerebrosidase (GALC) enzyme activity and galactosylsphingosine concentration (psychosine [PSY]). Normative information about PSY and GALC, derived from distinct samples of normal newborns, was used to develop the novel diagnostic tool. Bivariate normal limits (BVNL) were constructed, assuming a multivariate normal distribution of natural logarithms of GALC and PSY of normal newborns. The (lnGALC, lnPSY) points for newborns in various “abnormal groups,” including one group of infants who subsequently suffered EIKD, were plotted on a graph of BVNL. The points for all EIKD patients fell outside of BVNL (100% sensitivity). In a simulation study to compare the false-positive rate of existing univariate methods of diagnosis with our new BVNL-based method, we generated 100 million normal newborn data points. All fell within BVNL (i.e., zero false positives), whereas 5,682 false positives were observed when applying a two-tiered univariate method of the type suggested in the literature. These results suggest that (lnGALC, lnPSY) BVNLs will allow highly accurate prediction of EIKD, whereas two-tiered univariate approaches will not. Redevelopment of the BVNL based on GALCs and PSYs measured on a common large sample of normal newborns is required for NBS use.

KW - bivariate normal limits

KW - early identification

KW - early-onset disease

KW - followup

KW - late-onset disease

KW - newborn screening

UR - http://www.scopus.com/inward/record.url?scp=84990225189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990225189&partnerID=8YFLogxK

U2 - 10.1002/jnr.23793

DO - 10.1002/jnr.23793

M3 - Article

C2 - 27638594

AN - SCOPUS:84990225189

VL - 94

SP - 1084

EP - 1093

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 11

ER -